DrugDrug NameDrug Indication
DB11693VoclosporinNot Available
DB04106FotemustineNot Available
DB04572ThiotepaThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
DB04845IxabepiloneInvestigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
DB04849CediranibFor the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
DB04865Omacetaxine mepesuccinateUsed in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
DB04868NilotinibFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
DB04907EG009Intended for the treatment of brain cancer.
DB04951PirfenidoneFor the treatment of idiopathic pulmonary fibrosis (IPF).
DB04956AfelimomabInvestigated for use/treatment in sepsis and septicemia.
DB04996SatraplatinInvestigated for use/treatment in lung cancer, prostate cancer, and solid tumors.
DB05015BelinostatBelinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia [A19161].
DB05109TrabectedinIndicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors.
DB05168VintafolideInvestigated for use/treatment in solid tumors.
DB05259Glatiramer AcetateFor reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.
DB05294VandetanibVandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
DB05396Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
DB05459BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
DB05578RamucirumabFor use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
DB05676ApremilastInvestigated for use/treatment in psoriasis and psoriatic disorders.
DB05679UstekinumabUstekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB05812AbirateroneUsed in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
DB06168CanakinumabUsed in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
DB06176RomidepsinFor the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
DB06186IpilimumabIpilimumab is indicated for the treatment of unresectable or metastatic melanoma in adults. It is also used to reduce the risk of the deadly skin cancer returning after surgery.
DB06193PixantroneCurrently in Phase III investigation for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who have failed two prior lines of therapy. Presently, no standard therapy exists for patients with relapsed or refractory NHL. [2] After first line therapy has been initiated, most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracycline-induced congestive heart failure (CHF). Pixantrone is an attractive alternative as a second line agent, due to its lack of cardiac toxicity. [2] The phase III trial, PIX-R, is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large B-cell lymphoma (the most common type of NHL). Previous study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients. In myocardial strips which are doxorubicin naive, pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed, and once absorbed exhibits redox inactivity. [3] Pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia, diffuse large B-cell lymphoma, follicular lymphoma, metastatic breast cancer, low grade small lymphocytic lymphomas and general metastatic cancers.
DB06263AmrubicinInvestigated for use/treatment in lung cancer.
DB06273TocilizumabIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DB06287TemsirolimusFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
DB06366PertuzumabPertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DB06372RilonaceptRilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout.
DB06589PazopanibTreatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
DB06603PanobinostatPanobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
DB06612MepolizumabMepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history
DB06616BosutinibTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
DB06626AxitinibUsed in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
DB06650OfatumumabOfatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
DB06674GolimumabUsed in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
DB06681BelataceptFor prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
DB06688Sipuleucel-TSipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
DB06699DegarelixDegaralix is used for the management of advanced prostate cancer.
DB06719BuserelinBuserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
DB06769BendamustineBendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
DB06772CabazitaxelFor treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
DB06788HistrelinAs the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer.
DB06809PlerixaforUsed in combination with granulocyte-colony stimulating factor (G-CSF, filgrastim) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
DB06810PlicamycinFor the treatment of testicular cancer, as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer.
DB06813PralatrexateTreatment of relapsed or refractory peripheral T-cell lymphoma.
DB06825TriptorelinTriptorelin is indicated for the palliative treatment of advanced prostate cancer.
DB08486EfaproxiralNot Available
DB08828VismodegibVismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
DB08865CrizotinibCrizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
DB08868FingolimodFingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
DB08870Brentuximab vedotinUsed in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
DB08871EribulinFor the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
DB08875CabozantinibFor the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DB08877RuxolitinibTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
DB08879BelimumabAdjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
DB08880TeriflunomideUsed in the treatment of relapsing forms of multiple sclerosis (MS).
DB08881VemurafenibTreatment of unresectable or metastatic melanoma in patients with the BRAF-V600 mutation.
DB08889CarfilzomibCarfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
DB08895TofacitinibFor the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.
DB08896RegorafenibRegorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
DB08899EnzalutamideEnzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
DB08901PonatinibPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
DB08904Certolizumab pegolReducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
DB08905FormestaneFor the treatment of estrogen-receptor positive breast cancer in post-menopausal women.
DB08910PomalidomidePomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DB08911TrametinibTrametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
DB08912DabrafenibDabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
DB08916AfatinibAfatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
DB08935ObinutuzumabObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
DB09010CarmofurNot Available
DB09029SecukinumabFor the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy.
DB09031MiltefosineFor the treatment of mucosal (caused by Leishmania braziliensis), cutaneous (caused by L. braziliensis, L. guyanensis, and L. panamensis), and visceral leishmaniasis (caused by L. donovani). In comparing Leishmania drug susceptibility, it has been found that L. donovani is the most susceptible to miltefosine while L. major is the least susceptible. Off-label use includes treatment of free-living amebae (FLA) infections (unlabeled use; CDC, 2013).
DB09033VedolizumabVedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
DB09035NivolumabNivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.
DB09036SiltuximabSiltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
DB09037PembrolizumabPembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:  patients with unresectable or metastatic melanoma.  patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.  patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.  patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
DB09052BlinatumomabIndicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09053IbrutinibIbrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenström's Macroglobulinemia (WM).
DB09054IdelalisibIdelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
DB09063CeritinibCeritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DB09073PalbociclibPalbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DB09074OlaparibOlaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
DB09077DinutuximabDinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.
DB09078LenvatinibLenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
DB09079NintedanibNintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
DB09103AncestimNot Available
DB09122Peginterferon beta-1aFor the treatment of patients with relapsing forms of multiple sclerosis.
DB09143SonidegibSonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. (2)
DB09256TegafurIndicated for the treatment of cancer usually in combination with other biochemically modulating drugs.
DB09312Antilymphocyte immunoglobulin (horse)For prevention of renal transplant rejection and for the treatment of aplastic anemia.
DB09559NecitumumabNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
DB09570IxazomibIxazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
DB11364PidotimodFor use as immunostimulant therapy for treatment of cell-mediated immunosuppression with respiratory or urinary infections [L929].
DB11366RoquinimexInvestigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes.
DB11616PirarubicinNot Available
DB11617AclarubicinNot Available
DB11618ZorubicinNot Available
DB11678TreosulfanNot Available
DB11776BrodalumabBrodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
DB11800TivozanibNot Available
DB11996ThymopentinNot Available
DB12525MolgramostimNot Available
DB12692GusperimusNot Available
DB12699BalugrastimNot Available
DB12768BCG vaccineNot Available
DB12814Cepeginterferon alfa-2BNot Available
DB12832PrednimustineNot Available
DB12902TrofosfamideNot Available
DB12967MitoguazoneNot Available
DB13069NimustineNot Available
DB13144LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).
DB00002CetuximabCetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
DB00004Denileukin diftitoxFor treatment of cutaneous T-cell lymphoma
DB00005EtanerceptEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.
DB00007LeuprolideFor treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB00011Interferon alfa-n1For treatment of venereal or genital warts caused by the Human Papiloma Virus
DB00014GoserelinUsed to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
DB00019PegfilgrastimIncreases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant.
DB00020SargramostimFor the treatment of cancer and bone marrow transplant
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB00023AsparaginaseFor treatment of acute lympocytic leukemia and non-Hodgkins lymphoma
DB00026AnakinraFor the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
DB00034Interferon Alfa-2a, RecombinantFor the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
DB00038OprelvekinIncreases reduced platelet levels due to chemotherapy
DB00041AldesleukinFor treatment of adults with metastatic renal cell carcinoma.
DB00051AdalimumabFor treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
DB00056Gemtuzumab ozogamicinFor treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.
DB00059PegaspargaseFor treatment of acute lymphoblastic leukemia
DB00060Interferon beta-1aFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
DB00065InfliximabTo manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.
DB00068Interferon beta-1bInterferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
DB00069Interferon alfacon-1For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
DB00072TrastuzumabFor treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
DB00073RituximabFor treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
DB00074BasiliximabFor prophylactic treatment of kidney transplant rejection
DB00075MuromonabFor treatment of organ transplant recipients, prevention of organ rejection
DB00087AlemtuzumabAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
DB00091CyclosporineFor treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.
DB00092AlefaceptAs an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
DB00095EfalizumabFor the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
DB00098Antithymocyte immunoglobulin (rabbit)For prevention of renal transplant rejection
DB00099FilgrastimFilgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Tbo-filgrastim has a narrower indication profile than Neupogen - it is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies.
DB00105Interferon Alfa-2b, RecombinantFor the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
DB00106AbarelixFor palliative treatment of advanced prostate cancer.
DB00108NatalizumabFor treatment of multiple sclerosis.
DB00111DaclizumabZenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
DB00112BevacizumabAs part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
DB00179MasoprocolUsed for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).
DB00188BortezomibFor treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
DB00236PipobromanFor the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.
DB00242CladribineFor the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
DB00255DiethylstilbestrolUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
DB00261AnagrelideFor the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
DB00262CarmustineFor the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
DB00276AmsacrineFor treatment of acute myeloid leukaemia.
DB00290BleomycinFor palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
DB00291ChlorambucilFor treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
DB00293RaltitrexedFor the treatment of malignant neoplasm of colon and rectum
DB00305MitomycinFor treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
DB00307BexaroteneUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
DB00309VindesineFor the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
DB00317GefitinibFor the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
DB00352TioguanineFor remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
DB00357AminoglutethimideFor the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.
DB00361VinorelbineFor the treatment of non-small-cell lung carcinoma.
DB00385ValrubicinFor the treatment of cancer of the bladder.
DB00398SorafenibSorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
DB00428StreptozocinFor the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
DB00432TrifluridineOphthalmic solution for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.
DB00441GemcitabineGemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
DB00444TeniposideTeniposide is used for the treatment of refractory acute lymphoblastic leukaemia
DB00445EpirubicinFor use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
DB00480LenalidomideLenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
DB00488AltretamineFor use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
DB00499FlutamideFor the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
DB00515CisplatinFor the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
DB00523AlitretinoinFor topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
DB00526OxaliplatinUsed in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
DB00530ErlotinibFor the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
DB00531CyclophosphamideCyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
DB00539ToremifeneFor the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
DB00541VincristineTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
DB00544FluorouracilFor the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
DB00552PentostatinFor the treatment of hairy cell leukaemia refractory to alpha interferon.
DB00563MethotrexateMethotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.
DB00570VinblastineFor treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
DB00603Medroxyprogesterone acetateUsed as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
DB00619ImatinibFor the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
DB00631ClofarabineFor the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
DB00642PemetrexedUsed in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
DB00648MitotaneFor treatment of inoperable adrenocortical tumours; Cushing's syndrome
DB00665NilutamideFor use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).
DB00675TamoxifenTamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ.
DB00694DaunorubicinFor remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
DB00707Porfimer sodiumIndicated in the treatment of esophageal cancer.
DB00762IrinotecanFor the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
DB00773EtoposideFor use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
DB00851DacarbazineFor the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
DB00853TemozolomideFor the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.
DB00855Aminolevulinic acidAminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
DB00864TacrolimusFor use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
DB00877SirolimusFor the prophylaxis of organ rejection in patients receiving renal transplants.
DB00888MechlorethamineFor the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
DB00928AzacitidineFor treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
DB00947FulvestrantFor the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
DB00958CarboplatinFor the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
DB00970DactinomycinFor the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
DB00987CytarabineFor the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
DB00990ExemestaneFor the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
DB00992Methyl aminolevulinateFor topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).
DB00993AzathioprineFor use in rheumatoid arthritis, preventing renal transplant rejection, Crohn's disease, and colitis.
DB00997DoxorubicinDoxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
DB01005HydroxyureaFor management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
DB01006LetrozoleFor the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
DB01008BusulfanFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
DB01024Mycophenolic acidFor the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.
DB01030TopotecanFor the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
DB01033MercaptopurineFor remission induction and maintenance therapy of acute lymphatic leukemia.
DB01041ThalidomideFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
DB01042MelphalanFor the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
DB01073FludarabineFor the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
DB01097LeflunomideFor the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
DB01101CapecitabineFor the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
DB01128BicalutamideFor treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
DB01168ProcarbazineFor use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
DB01169Arsenic trioxideFor induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
DB01177IdarubicinFor the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
DB01181IfosfamideUsed as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
DB01196EstramustineFor the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
DB01204MitoxantroneFor the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
DB01206LomustineFor the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
DB01217AnastrozoleFor adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.
DB01229PaclitaxelUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
DB01248DocetaxelFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
DB01254DasatinibFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
DB01257EculizumabFor the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
DB01259LapatinibIndicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.
DB01262DecitabineFor treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores ≥0.5).
DB01268SunitinibFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
DB01269PanitumumabFor the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB01280NelarabineFor the treatment of pediatric and adult patients with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
DB01281AbataceptFor the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
DB01590EverolimusEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
DB02546VorinostatFor the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
DrugDrug NameTargetType
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
DB00004Denileukin diftitoxCytokine receptor common subunit gammatarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit betatarget
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB00005EtanerceptProstaglandin G/H synthase 2enzyme
DB00007LeuprolideGonadotropin-releasing hormone receptortarget
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00011Interferon alfa-n1Interferon alpha/beta receptor 2target
DB00011Interferon alfa-n1Interferon alpha/beta receptor 1target
DB00014GoserelinLutropin-choriogonadotropic hormone receptortarget
DB00014GoserelinGonadotropin-releasing hormone receptortarget
DB00019PegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB00019PegfilgrastimNeutrophil elastasetarget
DB00020SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB00020SargramostimBone marrow proteoglycantarget
DB00020SargramostimInterleukin-3 receptor subunit alphatarget
DB00020SargramostimCytokine receptor common subunit betatarget
DB00020SargramostimSyndecan-2target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00023AsparaginaseL-asparaginetarget
DB00026AnakinraInterleukin-1 receptor type 1target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 1target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 2target
DB00038OprelvekinInterleukin-11 receptor subunit alphatarget
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00051AdalimumabTumor necrosis factortarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00051AdalimumabComplement C1r subcomponenttarget
DB00051AdalimumabComplement C1q subcomponent subunit Atarget
DB00051AdalimumabComplement C1q subcomponent subunit Btarget
DB00051AdalimumabComplement C1q subcomponent subunit Ctarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00051AdalimumabComplement C1s subcomponenttarget
DB00051AdalimumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00059PegaspargaseL-asparaginetarget
DB00060Interferon beta-1aInterferon alpha/beta receptor 1target
DB00060Interferon beta-1aInterferon alpha/beta receptor 2target
DB00065InfliximabTumor necrosis factortarget
DB00068Interferon beta-1bInterferon alpha/beta receptor 1target
DB00068Interferon beta-1bInterferon alpha/beta receptor 2target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 1target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 2target
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00072TrastuzumabCytochrome P450 19A1enzyme
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00073RituximabComplement C1r subcomponenttarget
DB00073RituximabComplement C1q subcomponent subunit Atarget
DB00073RituximabComplement C1q subcomponent subunit Btarget
DB00073RituximabComplement C1q subcomponent subunit Ctarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00073RituximabComplement C1s subcomponenttarget
DB00073RituximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00074BasiliximabInterleukin-2 receptor subunit alphatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00074BasiliximabComplement C1r subcomponenttarget
DB00074BasiliximabComplement C1q subcomponent subunit Atarget
DB00074BasiliximabComplement C1q subcomponent subunit Btarget
DB00074BasiliximabComplement C1q subcomponent subunit Ctarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00074BasiliximabComplement C1s subcomponenttarget
DB00074BasiliximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00074BasiliximabInterleukin-2 receptor subunit betatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00091CyclosporineCalcium signal-modulating cyclophilin ligandtarget
DB00091CyclosporinePeptidyl-prolyl cis-trans isomerase Atarget
DB00091CyclosporineCalcineurin subunit B type 2target
DB00091CyclosporineCytochrome P450 3A5enzyme
DB00091CyclosporineCytochrome P450 3A4enzyme
DB00091CyclosporineCytochrome P450 3A7enzyme
DB00091CyclosporineMultidrug resistance protein 1transporter
DB00091CyclosporineCanalicular multispecific organic anion transporter 2transporter
DB00091CyclosporineBile salt export pumptransporter
DB00091CyclosporineMultidrug resistance-associated protein 1transporter
DB00091CyclosporineSolute carrier organic anion transporter family member 1A2transporter
DB00091CyclosporineIleal sodium/bile acid cotransportertransporter
DB00091CyclosporineSodium/bile acid cotransportertransporter
DB00091CyclosporineSolute carrier family 22 member 6transporter
DB00091CyclosporineMultidrug resistance-associated protein 7transporter
DB00091CyclosporineCanalicular multispecific organic anion transporter 1transporter
DB00091CyclosporineATP-binding cassette sub-family G member 2transporter
DB00091CyclosporineSolute carrier organic anion transporter family member 1B1transporter
DB00091CyclosporineCytochrome P450 2C19enzyme
DB00091CyclosporineCytochrome P450 2C8enzyme
DB00091CyclosporineCytochrome P450 2C9enzyme
DB00091CyclosporineCytochrome P450 2D6enzyme
DB00091CyclosporinePeptidyl-prolyl cis-trans isomerase F, mitochondrialtarget
DB00092AlefaceptT-cell surface antigen CD2target
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00092AlefaceptComplement C1r subcomponenttarget
DB00092AlefaceptComplement C1q subcomponent subunit Atarget
DB00092AlefaceptComplement C1q subcomponent subunit Btarget
DB00092AlefaceptComplement C1q subcomponent subunit Ctarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00092AlefaceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00095EfalizumabIntegrin alpha-Ltarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00095EfalizumabComplement C1r subcomponenttarget
DB00095EfalizumabComplement C1q subcomponent subunit Atarget
DB00095EfalizumabComplement C1q subcomponent subunit Btarget
DB00095EfalizumabComplement C1q subcomponent subunit Ctarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00095EfalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
DB00098Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
DB00098Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
DB00098Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DB00099FilgrastimGranulocyte colony-stimulating factor receptortarget
DB00099FilgrastimNeutrophil elastasetarget
DB00105Interferon Alfa-2b, RecombinantInterferon alpha/beta receptor 2target
DB00105Interferon Alfa-2b, RecombinantInterferon alpha/beta receptor 1target
DB00105Interferon Alfa-2b, RecombinantCytochrome P450 1A2enzyme
DB00106AbarelixGonadotropin-releasing hormone receptortarget
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00179MasoprocolArachidonate 5-lipoxygenasetarget
DB00179MasoprocolCytochrome P450 2J2enzyme
DB00179MasoprocolSex hormone-binding globulintarget
DB00188BortezomibCytochrome P450 3A4enzyme
DB00188BortezomibCytochrome P450 2C19enzyme
DB00188BortezomibCytochrome P450 1A2enzyme
DB00188BortezomibCytochrome P450 2D6enzyme
DB00188BortezomibCytochrome P450 2C9enzyme
DB00188BortezomibProteasome subunit beta type-5target
DB00188BortezomibProteasome subunit beta type-1target
DB00236PipobromanDNAtarget
DB00242CladribinePurine nucleoside phosphorylasetarget
DB00242CladribineDNAtarget
DB00242CladribineDeoxycytidine kinaseenzyme
DB00242CladribineRibonucleoside-diphosphate reductase large subunittarget
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2target
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2 Btarget
DB00242CladribineDNA polymerase alpha catalytic subunittarget
DB00242CladribineDNA polymerase epsilon catalytic subunit Atarget
DB00242CladribineDNA polymerase epsilon subunit 2target
DB00242CladribineDNA polymerase epsilon subunit 3target
DB00242CladribineDNA polymerase epsilon subunit 4target
DB00242CladribineSolute carrier family 22 member 2transporter
DB00242CladribineSolute carrier family 22 member 1transporter
DB00242CladribineATP-binding cassette sub-family G member 2transporter
DB00242CladribineSolute carrier family 28 member 3transporter
DB00255DiethylstilbestrolEstrogen receptor alphatarget
DB00255DiethylstilbestrolEstrogen-related receptor gammatarget
DB00255DiethylstilbestrolTransthyretincarrier
DB00255DiethylstilbestrolCatechol O-methyltransferaseenzyme
DB00255DiethylstilbestrolCytochrome P450 19A1enzyme
DB00255DiethylstilbestrolCytochrome P450 2A6enzyme
DB00255DiethylstilbestrolATP-binding cassette sub-family G member 2transporter
DB00255DiethylstilbestrolMultidrug resistance protein 1transporter
DB00255DiethylstilbestrolEstrogen receptor betatarget
DB00255DiethylstilbestrolCytochrome P450 3A4enzyme
DB00255DiethylstilbestrolCytochrome P450 2C8enzyme
DB00255DiethylstilbestrolCytochrome P450 2C9enzyme
DB00255DiethylstilbestrolCytochrome P450 2E1enzyme
DB00255DiethylstilbestrolSteroid hormone receptor ERR1target
DB00255DiethylstilbestrolSteroid hormone receptor ERR2target
DB00255DiethylstilbestrolNuclear receptor coactivator 2target
DB00255DiethylstilbestrolNuclear receptor subfamily 1 group I member 2target
DB00255DiethylstilbestrolAndrogen receptortarget
DB00255DiethylstilbestrolSex hormone-binding globulintarget
DB00261AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00261AnagrelideCytochrome P450 1A2enzyme
DB00262CarmustineGlutathione reductase, mitochondrialtarget
DB00262CarmustineDNAtarget
DB00262CarmustineCytochrome P450 1A2enzyme
DB00262CarmustineRNAtarget
DB00276AmsacrineDNA topoisomerase 2-alphatarget
DB00276AmsacrineDNAtarget
DB00276AmsacrinePotassium voltage-gated channel subfamily H member 2target
DB00276AmsacrineMultidrug resistance protein 1transporter
DB00276AmsacrineCytochrome P450 2D6enzyme
DB00276AmsacrineAlpha-1-acid glycoprotein 1target
DB00276AmsacrineSerum albumintarget
DB00290BleomycinDNA ligase 3target
DB00290BleomycinDNA ligase 1target
DB00290BleomycinDNAtarget
DB00290BleomycinBleomycin hydrolaseenzyme
DB00291ChlorambucilDNAtarget
DB00291ChlorambucilGlutathione S-transferase Penzyme
DB00291ChlorambucilSolute carrier organic anion transporter family member 1A2transporter
DB00293RaltitrexedThymidylate synthasetarget
DB00293RaltitrexedFolylpolyglutamate synthase, mitochondrialtarget
DB00305MitomycinDNAtarget
DB00305MitomycinNADPH--cytochrome P450 reductaseenzyme
DB00305MitomycinMultidrug resistance protein 1transporter
DB00307BexaroteneRetinoic acid receptor RXR-betatarget
DB00307BexaroteneCytochrome P450 3A4enzyme
DB00307BexaroteneRetinoic acid receptor RXR-alphatarget
DB00307BexaroteneRetinoic acid receptor RXR-gammatarget
DB00307BexaroteneCytochrome P450 2C9enzyme
DB00309VindesineTubulin beta-1 chaintarget
DB00309VindesineCytochrome P450 3A4enzyme
DB00317GefitinibEpidermal growth factor receptortarget
DB00317GefitinibCytochrome P450 3A4enzyme
DB00317GefitinibCytochrome P450 2D6enzyme
DB00317GefitinibMultidrug resistance protein 1transporter
DB00317GefitinibATP-binding cassette sub-family G member 2transporter
DB00317GefitinibCytochrome P450 3A5enzyme
DB00317GefitinibCytochrome P450 1A1enzyme
DB00317GefitinibCytochrome P450 2C9enzyme
DB00317GefitinibCytochrome P450 2C19enzyme
DB00317GefitinibSerum albumincarrier
DB00317GefitinibAlpha-1-acid glycoprotein 1carrier
DB00352TioguanineDNAtarget
DB00352TioguanineMultidrug resistance-associated protein 4transporter
DB00352TioguanineHypoxanthine-guanine phosphoribosyltransferaseenzyme
DB00357AminoglutethimideCytochrome P450 19A1target
DB00357AminoglutethimideCytochrome P450 1A2enzyme
DB00357AminoglutethimideCytochrome P450 2C19enzyme
DB00357AminoglutethimideCytochrome P450 3A4enzyme
DB00357AminoglutethimideCholesterol side-chain cleavage enzyme, mitochondrialtarget
DB00361VinorelbineTubulin beta chaintarget
DB00361VinorelbineCytochrome P450 3A4enzyme
DB00361VinorelbineMultidrug resistance protein 1transporter
DB00361VinorelbineCytochrome P450 2D6enzyme
DB00385ValrubicinDNA topoisomerase 2-alphatarget
DB00385ValrubicinDNAtarget
DB00398SorafenibSerine/threonine-protein kinase B-raftarget
DB00398SorafenibReceptor-type tyrosine-protein kinase FLT3target
DB00398SorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB00398SorafenibVascular endothelial growth factor receptor 3target
DB00398SorafenibPlatelet-derived growth factor receptor betatarget
DB00398SorafenibMast/stem cell growth factor receptor Kittarget
DB00398SorafenibVascular endothelial growth factor receptor 2target
DB00398SorafenibCytochrome P450 3A4enzyme
DB00398SorafenibUDP-glucuronosyltransferase 1-9enzyme
DB00398SorafenibCytochrome P450 2B6enzyme
DB00398SorafenibCytochrome P450 2C8enzyme
DB00398SorafenibCytochrome P450 3A5enzyme
DB00398SorafenibCytochrome P450 3A7enzyme
DB00398SorafenibCytochrome P450 2C9enzyme
DB00398SorafenibMultidrug resistance-associated protein 4transporter
DB00398SorafenibMultidrug resistance protein 1transporter
DB00398SorafenibCanalicular multispecific organic anion transporter 1transporter
DB00398SorafenibATP-binding cassette sub-family G member 2transporter
DB00398SorafenibCytochrome P450 1A2enzyme
DB00398SorafenibCytochrome P450 2C19enzyme
DB00398SorafenibCytochrome P450 2D6enzyme
DB00398SorafenibUDP-glucuronosyltransferase 1-1enzyme
DB00398SorafenibRalA-binding protein 1transporter
DB00398SorafenibFibroblast growth factor receptor 1target
DB00398SorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB00398SorafenibVascular endothelial growth factor receptor 1target
DB00428StreptozocinDNAtarget
DB00428StreptozocinMultidrug resistance protein 1transporter
DB00428StreptozocinSolute carrier family 2, facilitated glucose transporter member 2target
DB00428StreptozocinO-GlcNAcase BT_4395target
DB00428StreptozocinCytochrome P450 1A1enzyme
DB00428StreptozocinCytochrome P450 1A2enzyme
DB00428StreptozocinCytochrome P450 2E1enzyme
DB00428StreptozocinBifunctional protein NCOATtarget
DB00432TrifluridineThymidylate synthasetarget
DB00432TrifluridineDNAtarget
DB00432TrifluridineThymidine kinase, cytosolicenzyme
DB00432TrifluridineThymidine phosphorylaseenzyme
DB00432TrifluridineSolute carrier family 22 member 6transporter
DB00441GemcitabineRibonucleoside-diphosphate reductase large subunittarget
DB00441GemcitabineUMP-CMP kinasetarget
DB00441GemcitabineThymidylate synthasetarget
DB00441GemcitabineCytidine deaminaseenzyme
DB00441GemcitabineDeoxycytidine kinaseenzyme
DB00441GemcitabineMultidrug resistance protein 1transporter
DB00441GemcitabineMultidrug resistance-associated protein 7transporter
DB00441GemcitabineEquilibrative nucleoside transporter 1transporter
DB00441GemcitabineDNAtarget
DB00441GemcitabineSodium/nucleoside cotransporter 1transporter
DB00441GemcitabineEquilibrative nucleoside transporter 2transporter
DB00441GemcitabineSolute carrier family 28 member 3transporter
DB00444TeniposideDNA topoisomerase 2-alphatarget
DB00444TeniposideCytochrome P450 2C19enzyme
DB00444TeniposideCytochrome P450 2C9enzyme
DB00444TeniposideCytochrome P450 3A4enzyme
DB00444TeniposideMultidrug resistance-associated protein 6transporter
DB00444TeniposideATP-binding cassette sub-family G member 2transporter
DB00444TeniposideCytochrome P450 3A5enzyme
DB00445EpirubicinChromodomain-helicase-DNA-binding protein 1target
DB00445EpirubicinDNA topoisomerase 2-alphatarget
DB00445EpirubicinDNAtarget
DB00445EpirubicinMultidrug resistance-associated protein 1transporter
DB00445EpirubicinUDP-glucuronosyltransferase 2B7enzyme
DB00445EpirubicinCytosolic phospholipase A2enzyme
DB00480LenalidomideProstaglandin G/H synthase 2target
DB00480LenalidomideTumor necrosis factor ligand superfamily member 11target
DB00480LenalidomideCadherin-5target
DB00480LenalidomideProtein cereblontarget
DB00480LenalidomideMultidrug resistance protein 1transporter
DB00488AltretamineDNAtarget
DB00499FlutamideAndrogen receptortarget
DB00499FlutamideCytochrome P450 1A2enzyme
DB00499FlutamideCytochrome P450 3A4enzyme
DB00499FlutamideCytochrome P450 1A1enzyme
DB00499FlutamideCytochrome P450 1B1enzyme
DB00499FlutamideCytochrome P450 2C19enzyme
DB00499FlutamideCytochrome P450 3A5enzyme
DB00499FlutamideAryl hydrocarbon receptortarget
DB00499FlutamideNuclear receptor subfamily 1 group I member 2target
DB00515CisplatinDNAtarget
DB00515CisplatinCanalicular multispecific organic anion transporter 2transporter
DB00515CisplatinMultidrug resistance-associated protein 5transporter
DB00515CisplatinCanalicular multispecific organic anion transporter 1transporter
DB00515CisplatinSolute carrier family 22 member 2transporter
DB00515CisplatinHigh affinity copper uptake protein 1transporter
DB00515CisplatinProbable low affinity copper uptake protein 2transporter
DB00515CisplatinMultidrug resistance-associated protein 6transporter
DB00515CisplatinMultidrug resistance protein 1transporter
DB00515CisplatinCopper-transporting ATPase 2transporter
DB00515CisplatinCopper-transporting ATPase 1transporter
DB00515CisplatinProstaglandin G/H synthase 2enzyme
DB00515CisplatinMyeloperoxidaseenzyme
DB00515CisplatinXanthine dehydrogenase/oxidaseenzyme
DB00515CisplatinArylamine N-acetyltransferaseenzyme
DB00515CisplatinCytochrome P450 2C9enzyme
DB00515CisplatinCytochrome P450 2B6enzyme
DB00515CisplatinCholinesteraseenzyme
DB00515CisplatinCytochrome P450 4A11enzyme
DB00515CisplatinATP-binding cassette sub-family G member 2transporter
DB00515CisplatinGlutathione S-transferase theta-1enzyme
DB00515CisplatinMetallothionein-1Aenzyme
DB00515CisplatinMetallothionein-2enzyme
DB00515CisplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00515CisplatinGlutathione S-transferase Penzyme
DB00515CisplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00515CisplatinGlutathione S-transferase Mu 1enzyme
DB00515CisplatinDNA-3-methyladenine glycosylasetarget
DB00515CisplatinAlpha-2-macroglobulintarget
DB00515CisplatinSerum albumincarrier
DB00515CisplatinSerotransferrintarget
DB00515CisplatinCopper transport protein ATOX1target
DB00523AlitretinoinRetinoic acid receptor alphatarget
DB00523AlitretinoinRetinoic acid receptor RXR-betatarget
DB00523AlitretinoinRetinoic acid receptor gammatarget
DB00523AlitretinoinRetinoic acid receptor betatarget
DB00523AlitretinoinRetinoic acid receptor RXR-gammatarget
DB00523AlitretinoinRetinoic acid receptor RXR-alphatarget
DB00523AlitretinoinCellular retinoic acid-binding protein 2carrier
DB00523AlitretinoinCellular retinoic acid-binding protein 1carrier
DB00523AlitretinoinMultidrug resistance protein 1transporter
DB00523AlitretinoinCytochrome P450 1A2enzyme
DB00523AlitretinoinInsulin-like growth factor-binding protein 3target
DB00523AlitretinoinPregnancy-specific beta-1-glycoprotein 5target
DB00523AlitretinoinCytochrome P450 26C1target
DB00526OxaliplatinDNAtarget
DB00526OxaliplatinSolute carrier family 22 member 2transporter
DB00526OxaliplatinSolute carrier family 22 member 1transporter
DB00526OxaliplatinHigh affinity copper uptake protein 1transporter
DB00526OxaliplatinSolute carrier family 22 member 3transporter
DB00526OxaliplatinATP-binding cassette sub-family G member 2transporter
DB00526OxaliplatinCytochrome P450 1A1enzyme
DB00526OxaliplatinCytochrome P450 1A2enzyme
DB00526OxaliplatinCytochrome P450 1B1enzyme
DB00526OxaliplatinCytochrome P450 2E1enzyme
DB00526OxaliplatinGlutathione S-transferase theta-1enzyme
DB00526OxaliplatinMetallothionein-1Aenzyme
DB00526OxaliplatinMetallothionein-2enzyme
DB00526OxaliplatinMyeloperoxidaseenzyme
DB00526OxaliplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00526OxaliplatinGlutathione S-transferase Penzyme
DB00526OxaliplatinGlutathione S-transferase Mu 1enzyme
DB00526OxaliplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00526OxaliplatinCanalicular multispecific organic anion transporter 1transporter
DB00526OxaliplatinCopper-transporting ATPase 2transporter
DB00526OxaliplatinCopper-transporting ATPase 1transporter
DB00530ErlotinibEpidermal growth factor receptortarget
DB00530ErlotinibCytochrome P450 3A4enzyme
DB00530ErlotinibATP-binding cassette sub-family G member 2transporter
DB00530ErlotinibMultidrug resistance protein 1transporter
DB00530ErlotinibNuclear receptor subfamily 1 group I member 2target
DB00530ErlotinibCytochrome P450 3A5enzyme
DB00530ErlotinibCytochrome P450 1A1enzyme
DB00530ErlotinibCytochrome P450 1A2enzyme
DB00530ErlotinibCytochrome P450 1B1enzyme
DB00530ErlotinibCytochrome P450 2D6enzyme
DB00530ErlotinibCytochrome P450 2C8enzyme
DB00530ErlotinibUDP-glucuronosyltransferase 1-1enzyme
DB00530ErlotinibSerum albumincarrier
DB00530ErlotinibAlpha-1-acid glycoprotein 1carrier
DB00531CyclophosphamideDNAtarget
DB00531CyclophosphamideCytochrome P450 2B6enzyme
DB00531CyclophosphamideCytochrome P450 2C9enzyme
DB00531CyclophosphamideCytochrome P450 3A4enzyme
DB00531CyclophosphamideCytochrome P450 2C19enzyme
DB00531CyclophosphamideMultidrug resistance protein 1transporter
DB00531CyclophosphamideCytochrome P450 2A6enzyme
DB00531CyclophosphamideCytochrome P450 2C18enzyme
DB00531CyclophosphamideCytochrome P450 2C8enzyme
DB00531CyclophosphamideCytochrome P450 2D6enzyme
DB00531CyclophosphamideCytochrome P450 3A7enzyme
DB00531CyclophosphamideCytochrome P450 3A5enzyme
DB00531CyclophosphamideNuclear receptor subfamily 1 group I member 2target
DB00539ToremifeneEstrogen receptor alphatarget
DB00539ToremifeneCytochrome P450 3A4enzyme
DB00539ToremifeneMultidrug resistance protein 1transporter
DB00539ToremifeneCytochrome P450 1A1enzyme
DB00539ToremifeneCytochrome P450 1A2enzyme
DB00539ToremifeneSex hormone-binding globulintarget
DB00541VincristineTubulin beta chaintarget
DB00541VincristineCytochrome P450 3A4enzyme
DB00541VincristineCytochrome P450 3A5enzyme
DB00541VincristineCytochrome P450 3A7enzyme
DB00541VincristineMultidrug resistance protein 1transporter
DB00541VincristineCanalicular multispecific organic anion transporter 2transporter
DB00541VincristineSolute carrier family 22 member 3transporter
DB00541VincristineMultidrug resistance-associated protein 1transporter
DB00541VincristineMultidrug resistance-associated protein 7transporter
DB00541VincristineCanalicular multispecific organic anion transporter 1transporter
DB00541VincristineBile salt export pumptransporter
DB00541VincristineATP-binding cassette sub-family G member 2transporter
DB00541VincristineTubulin alpha-4A chaintarget
DB00541VincristineRalA-binding protein 1transporter
DB00544FluorouracilThymidylate synthasetarget
DB00544FluorouracilCytochrome P450 1A2enzyme
DB00544FluorouracilThymidine phosphorylaseenzyme
DB00544FluorouracilSerum albumincarrier
DB00544FluorouracilCytochrome P450 2C9enzyme
DB00544FluorouracilDihydropyrimidine dehydrogenase [NADP(+)]enzyme
DB00544FluorouracilUridine phosphorylase 1enzyme
DB00544FluorouracilUridine phosphorylase 2enzyme
DB00544FluorouracilDNAtarget
DB00544FluorouracilRNAtarget
DB00544FluorouracilCytochrome P450 2A6enzyme
DB00544FluorouracilCytochrome P450 2C8enzyme
DB00544FluorouracilMethylenetetrahydrofolate reductaseenzyme
DB00544FluorouracilThymidylate synthaseenzyme
DB00544FluorouracilUridine 5'-monophosphate synthaseenzyme
DB00544FluorouracilAmidophosphoribosyltransferaseenzyme
DB00544FluorouracilSolute carrier family 22 member 7transporter
DB00544FluorouracilEquilibrative nucleoside transporter 1transporter
DB00544FluorouracilATP-binding cassette sub-family G member 2transporter
DB00544FluorouracilCanalicular multispecific organic anion transporter 2transporter
DB00544FluorouracilMultidrug resistance-associated protein 4transporter
DB00544FluorouracilMultidrug resistance-associated protein 5transporter
DB00552PentostatinAdenosine deaminasetarget
DB00563MethotrexateDihydrofolate reductasetarget
DB00563MethotrexateAldehyde oxidaseenzyme
DB00563MethotrexateMethylenetetrahydrofolate reductaseenzyme
DB00563MethotrexateSerum albumincarrier
DB00563MethotrexateCanalicular multispecific organic anion transporter 2transporter
DB00563MethotrexateMultidrug resistance-associated protein 4transporter
DB00563MethotrexateMultidrug resistance-associated protein 1transporter
DB00563MethotrexateSolute carrier family 22 member 6transporter
DB00563MethotrexateMultidrug resistance-associated protein 7transporter
DB00563MethotrexateSolute carrier family 22 member 8transporter
DB00563MethotrexateCanalicular multispecific organic anion transporter 1transporter
DB00563MethotrexateMultidrug resistance protein 1transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1A2transporter
DB00563MethotrexateMonocarboxylate transporter 1transporter
DB00563MethotrexateATP-binding cassette sub-family C member 11transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1B3transporter
DB00563MethotrexateSolute carrier family 22 member 11transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1C1transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 3A1transporter
DB00563MethotrexateATP-binding cassette sub-family G member 2transporter
DB00563MethotrexateSolute carrier family 22 member 7transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1B1transporter
DB00563Methotrexate6-phosphogluconate dehydrogenase, decarboxylatingenzyme
DB00563MethotrexateProton-coupled folate transportertransporter
DB00563MethotrexateFolylpolyglutamate synthase, mitochondrialenzyme
DB00563MethotrexateGamma-glutamyl hydrolaseenzyme
DB00563MethotrexateDihydrofolate reductaseenzyme
DB00563MethotrexateThymidylate synthaseenzyme
DB00563MethotrexateBifunctional purine biosynthesis protein PURHenzyme
DB00563MethotrexateSolute carrier organic anion transporter family member 4C1transporter
DB00563MethotrexateFolate transporter 1transporter
DB00563MethotrexateFolate receptor alphatransporter
DB00570VinblastineTubulin beta chaintarget
DB00570VinblastineTranscription factor AP-1target
DB00570VinblastineCytochrome P450 3A4enzyme
DB00570VinblastineMultidrug resistance protein 1transporter
DB00570VinblastineMultidrug resistance-associated protein 1transporter
DB00570VinblastineCanalicular multispecific organic anion transporter 1transporter
DB00570VinblastineMultidrug resistance-associated protein 6transporter
DB00570VinblastineBile salt export pumptransporter
DB00570VinblastineSolute carrier family 22 member 2transporter
DB00570VinblastineTubulin alpha-1A chaintarget
DB00570VinblastineTubulin delta chaintarget
DB00570VinblastineTubulin epsilon chaintarget
DB00570VinblastineTubulin gamma-1 chaintarget
DB00570VinblastineCytochrome P450 2D6enzyme
DB00603Medroxyprogesterone acetateProgesterone receptortarget
DB00603Medroxyprogesterone acetateEstrogen receptor alphatarget
DB00603Medroxyprogesterone acetateCytochrome P450 3A4enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C8enzyme
DB00603Medroxyprogesterone acetate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C9enzyme
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB00631ClofarabineDNA polymerase alpha catalytic subunittarget
DB00631ClofarabineRibonucleoside-diphosphate reductase large subunittarget
DB00631ClofarabineDeoxycytidine kinaseenzyme
DB00631ClofarabineDNAtarget
DB00631ClofarabineATP-binding cassette sub-family G member 2transporter
DB00642PemetrexedThymidylate synthasetarget
DB00642PemetrexedDihydrofolate reductasetarget
DB00642PemetrexedTrifunctional purine biosynthetic protein adenosine-3target
DB00642PemetrexedDeoxycytidine kinaseenzyme
DB00642PemetrexedBifunctional purine biosynthesis protein PURHtarget
DB00642PemetrexedEquilibrative nucleoside transporter 1enzyme
DB00648MitotaneCytochrome P450 11B1, mitochondrialtarget
DB00648MitotaneAdrenodoxin, mitochondrialtarget
DB00648MitotaneSex hormone-binding globulincarrier
DB00648MitotaneCorticosteroid-binding globulincarrier
DB00648MitotaneCytochrome P450 3A4enzyme
DB00648MitotaneEstrogen receptor alphatarget
DB00648MitotaneProgesterone receptortarget
DB00648MitotaneAndrogen receptortarget
DB00665NilutamideAndrogen receptortarget
DB00665NilutamideCytochrome P450 2C19enzyme
DB00665NilutamideNADPH--cytochrome P450 reductaseenzyme
DB00665NilutamideCytochrome P450 2C8enzyme
DB00665NilutamideCytochrome P450 2C9enzyme
DB00675TamoxifenEstrogen receptor alphatarget
DB00675TamoxifenEstrogen receptor betatarget
DB00675TamoxifenCytochrome P450 2C9enzyme
DB00675TamoxifenCytochrome P450 3A4enzyme
DB00675TamoxifenCytochrome P450 2D6enzyme
DB00675TamoxifenCytochrome P450 2C8enzyme
DB00675TamoxifenCytochrome P450 2B6enzyme
DB00675TamoxifenLiver carboxylesterase 1enzyme
DB00675TamoxifenCytochrome P450 3A5enzyme
DB00675TamoxifenCytochrome P450 1A1enzyme
DB00675TamoxifenCytochrome P450 1A2enzyme
DB00675TamoxifenCytochrome P450 1B1enzyme
DB00675TamoxifenCytochrome P450 2C19enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00675TamoxifenCytochrome P450 3A7enzyme
DB00675TamoxifenMultidrug resistance protein 1transporter
DB00675TamoxifenBile salt export pumptransporter
DB00675TamoxifenATP-binding cassette sub-family G member 2transporter
DB00675TamoxifenCytochrome P450 19A1enzyme
DB00675TamoxifenCytochrome P450 2A6enzyme
DB00675TamoxifenCytochrome P450 2E1enzyme
DB00675TamoxifenUDP-glucuronosyltransferase 1-10enzyme
DB00675TamoxifenSulfotransferase 1A1enzyme
DB00675TamoxifenCanalicular multispecific organic anion transporter 1transporter
DB00675Tamoxifen3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerasetarget
DB00675TamoxifenProtein kinase Ctarget
DB00675TamoxifenAndrogen receptortarget
DB00675TamoxifenPotassium voltage-gated channel subfamily H member 2target
DB00675TamoxifenNuclear receptor subfamily 1 group I member 2target
DB00675TamoxifenEstrogen-related receptor gammatarget
DB00675TamoxifenSex hormone-binding globulintarget
DB00694DaunorubicinDNAtarget
DB00694DaunorubicinXanthine dehydrogenase/oxidaseenzyme
DB00694DaunorubicinCytochrome P450 3A5enzyme
DB00694DaunorubicinNADPH--cytochrome P450 reductaseenzyme
DB00694DaunorubicinMultidrug resistance protein 1transporter
DB00694DaunorubicinMultidrug resistance-associated protein 1transporter
DB00694DaunorubicinCanalicular multispecific organic anion transporter 1transporter
DB00694DaunorubicinSolute carrier family 22 member 2transporter
DB00694DaunorubicinMultidrug resistance-associated protein 6transporter
DB00694DaunorubicinBile salt export pumptransporter
DB00694DaunorubicinMultidrug resistance-associated protein 7transporter
DB00694DaunorubicinATP-binding cassette sub-family G member 2transporter
DB00694DaunorubicinDNA topoisomerase 2-alphatarget
DB00694DaunorubicinDNA topoisomerase 2-betatarget
DB00694DaunorubicinCytochrome P450 1A1enzyme
DB00694DaunorubicinCytochrome P450 1A2enzyme
DB00694DaunorubicinCytochrome P450 1B1enzyme
DB00694DaunorubicinCytochrome P450 3A4enzyme
DB00707Porfimer sodiumLow-density lipoprotein receptortarget
DB00707Porfimer sodiumHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00762IrinotecanDNA topoisomerase I, mitochondrialtarget
DB00762IrinotecanDNA topoisomerase 1target
DB00762IrinotecanCytochrome P450 3A4enzyme
DB00762IrinotecanCytochrome P450 3A5enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-1enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-9enzyme
DB00762IrinotecanLiver carboxylesterase 1enzyme
DB00762IrinotecanCytochrome P450 3A7enzyme
DB00762IrinotecanCytochrome P450 2B6enzyme
DB00762IrinotecanSolute carrier family 22 member 3transporter
DB00762IrinotecanSolute carrier organic anion transporter family member 1B1transporter
DB00762IrinotecanMultidrug resistance-associated protein 1transporter
DB00762IrinotecanATP-binding cassette sub-family G member 2transporter
DB00762IrinotecanSerum albumincarrier
DB00762IrinotecanCocaine esteraseenzyme
DB00762IrinotecanCholinesteraseenzyme
DB00762IrinotecanMultidrug resistance protein 1transporter
DB00762IrinotecanCanalicular multispecific organic anion transporter 1transporter
DB00773EtoposideDNA topoisomerase 2-alphatarget
DB00773EtoposideCytochrome P450 3A4enzyme
DB00773EtoposideCanalicular multispecific organic anion transporter 2transporter
DB00773EtoposideMultidrug resistance-associated protein 6transporter
DB00773EtoposideMultidrug resistance protein 1transporter
DB00773EtoposideMultidrug resistance-associated protein 1transporter
DB00773EtoposideMultidrug resistance-associated protein 7transporter
DB00773EtoposideCanalicular multispecific organic anion transporter 1transporter
DB00773EtoposideATP-binding cassette sub-family G member 2transporter
DB00773EtoposideCytochrome P450 1A2enzyme
DB00773EtoposideCytochrome P450 2C8enzyme
DB00773EtoposideCytochrome P450 2E1enzyme
DB00773EtoposideCytochrome P450 3A5enzyme
DB00773EtoposideUDP-glucuronosyltransferase 1-1enzyme
DB00773EtoposideDNA topoisomerase 2-betatarget
DB00773EtoposideGlutathione S-transferase theta-1enzyme
DB00773EtoposideGlutathione S-transferase Penzyme
DB00773EtoposideProstaglandin G/H synthase 2enzyme
DB00773EtoposideProstaglandin G/H synthase 1enzyme
DB00851DacarbazineDNA polymerase alpha subunit Btarget
DB00851DacarbazineCytochrome P450 1A1enzyme
DB00851DacarbazineCytochrome P450 1A2enzyme
DB00851DacarbazineCytochrome P450 2E1enzyme
DB00851Dacarbazine6-phosphogluconate dehydrogenase, decarboxylatingtarget
DB00851DacarbazineDNAtarget
DB00853TemozolomideDNAtarget
DB00853TemozolomideCytochrome P450 3A4enzyme
DB00855Aminolevulinic acidDelta-aminolevulinic acid dehydratasetarget
DB00855Aminolevulinic acidSolute carrier family 15 member 1transporter
DB00855Aminolevulinic acidSolute carrier family 15 member 2transporter
DB00864TacrolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00864TacrolimusCytochrome P450 3A4enzyme
DB00864TacrolimusCytochrome P450 3A5enzyme
DB00864TacrolimusCytochrome P450 3A7enzyme
DB00864TacrolimusMultidrug resistance protein 1transporter
DB00864TacrolimusATP-binding cassette sub-family A member 5transporter
DB00864TacrolimusSerum albumincarrier
DB00864TacrolimusAlpha-1-acid glycoprotein 1carrier
DB00877SirolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00877SirolimusCytochrome P450 3A4enzyme
DB00877SirolimusSerine/threonine-protein kinase mTORtarget
DB00877SirolimusFibroblast growth factor 2target
DB00877SirolimusCytochrome P450 3A5enzyme
DB00877SirolimusCytochrome P450 3A7enzyme
DB00877SirolimusMultidrug resistance protein 1transporter
DB00877SirolimusSolute carrier organic anion transporter family member 1B1transporter
DB00877SirolimusMultidrug and toxin extrusion protein 1transporter
DB00888MechlorethamineDNAtarget
DB00928AzacitidineDNA (cytosine-5)-methyltransferase 1target
DB00928AzacitidineCytidine deaminaseenzyme
DB00928AzacitidineDNAtarget
DB00928AzacitidineRNAtarget
DB00947FulvestrantEstrogen receptor alphatarget
DB00947FulvestrantCytochrome P450 3A4enzyme
DB00958CarboplatinDNAtarget
DB00958CarboplatinHigh affinity copper uptake protein 1transporter
DB00958CarboplatinProbable low affinity copper uptake protein 2transporter
DB00958CarboplatinXanthine dehydrogenase/oxidaseenzyme
DB00958CarboplatinMyeloperoxidaseenzyme
DB00958CarboplatinGlutathione S-transferase theta-1enzyme
DB00958CarboplatinMetallothionein-1Aenzyme
DB00958CarboplatinMetallothionein-2enzyme
DB00958CarboplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00958CarboplatinGlutathione S-transferase Penzyme
DB00958CarboplatinGlutathione S-transferase Mu 1enzyme
DB00958CarboplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00958CarboplatinCopper-transporting ATPase 1transporter
DB00958CarboplatinCopper-transporting ATPase 2transporter
DB00958CarboplatinATP-binding cassette sub-family G member 2transporter
DB00958CarboplatinCanalicular multispecific organic anion transporter 1transporter
DB00970DactinomycinDNAtarget
DB00970DactinomycinSolute carrier family 22 member 5transporter
DB00970DactinomycinMultidrug resistance protein 1transporter
DB00970DactinomycinMultidrug resistance-associated protein 6transporter
DB00970DactinomycinMultidrug resistance-associated protein 1transporter
DB00970DactinomycinATP-binding cassette sub-family G member 2transporter
DB00970DactinomycinDNA topoisomerase 2target
DB00987CytarabineDNA polymerase betatarget
DB00987CytarabineCytidine deaminaseenzyme
DB00987CytarabineSolute carrier family 22 member 2transporter
DB00987CytarabineSolute carrier family 22 member 1transporter
DB00987CytarabineMultidrug resistance-associated protein 7transporter
DB00987CytarabineEquilibrative nucleoside transporter 1transporter
DB00987CytarabineDNAtarget
DB00987CytarabineCytochrome P450 3A4enzyme
DB00987CytarabineDeoxycytidine kinaseenzyme
DB00987Cytarabine5'-nucleotidaseenzyme
DB00987CytarabineDeoxycytidylate deaminaseenzyme
DB00990ExemestaneCytochrome P450 19A1target
DB00990ExemestaneCytochrome P450 3A4enzyme
DB00990ExemestaneCytochrome P450 19A1enzyme
DB00992Methyl aminolevulinateHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00993AzathioprineHypoxanthine-guanine phosphoribosyltransferasetarget
DB00993AzathioprineThiopurine S-methyltransferaseenzyme
DB00993AzathioprineXanthine dehydrogenase/oxidaseenzyme
DB00993AzathioprineGlutathione S-transferase A1enzyme
DB00993AzathioprineGlutathione S-transferase A2enzyme
DB00993AzathioprineGlutathione S-transferase Mu 1enzyme
DB00993AzathioprineRas-related C3 botulinum toxin substrate 1target
DB00997DoxorubicinDNA topoisomerase 2-alphatarget
DB00997DoxorubicinDNAtarget
DB00997DoxorubicinCytochrome P450 3A4enzyme
DB00997DoxorubicinCytochrome P450 2D6enzyme
DB00997DoxorubicinCytochrome P450 2B6enzyme
DB00997DoxorubicinMultidrug resistance protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 2transporter
DB00997DoxorubicinMultidrug resistance-associated protein 6transporter
DB00997DoxorubicinMultidrug resistance-associated protein 1transporter
DB00997DoxorubicinMultidrug resistance-associated protein 7transporter
DB00997DoxorubicinATP-binding cassette sub-family G member 2transporter
DB00997DoxorubicinBile salt export pumptransporter
DB00997DoxorubicinSolute carrier family 22 member 16transporter
DB00997DoxorubicinATP-binding cassette sub-family B member 8, mitochondrialtransporter
DB00997DoxorubicinCytochrome P450 1B1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 3enzyme
DB00997DoxorubicinAlcohol dehydrogenase [NADP(+)]enzyme
DB00997DoxorubicinAldo-keto reductase family 1 member C3enzyme
DB00997DoxorubicinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00997DoxorubicinXanthine dehydrogenase/oxidaseenzyme
DB00997DoxorubicinNitric oxide synthase, endothelialenzyme
DB00997DoxorubicinNitric oxide synthase, inducibleenzyme
DB00997DoxorubicinNitric oxide synthase, brainenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme
DB00997DoxorubicinNADPH--cytochrome P450 reductaseenzyme
DB00997DoxorubicinRalA-binding protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 1transporter
DB00997DoxorubicinSerum albumincarrier
DB00997DoxorubicinNucleolar and coiled-body phosphoprotein 1target
DB01005HydroxyureaRibonucleoside-diphosphate reductase large subunittarget
DB01005HydroxyureaCytochrome P450 2D6enzyme
DB01006LetrozoleCytochrome P450 19A1target
DB01006LetrozoleCytochrome P450 3A4enzyme
DB01006LetrozoleCytochrome P450 2A6enzyme
DB01006LetrozoleCytochrome P450 19A1enzyme
DB01008BusulfanDNAtarget
DB01008BusulfanCytochrome P450 3A4enzyme
DB01008BusulfanGlutathione S-transferase A2enzyme
DB01008BusulfanGlutathione S-transferase A1enzyme
DB01008BusulfanGlutathione S-transferase Mu 1enzyme
DB01008BusulfanGlutathione S-transferase Penzyme
DB01008BusulfanMicrosomal glutathione S-transferase 2enzyme
DB01024Mycophenolic acidInosine-5'-monophosphate dehydrogenase 2target
DB01024Mycophenolic acidInosine-5'-monophosphate dehydrogenase 1target
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-1enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-9enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 2B7enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-7enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-6enzyme
DB01030TopotecanDNA topoisomerase I, mitochondrialtarget
DB01030TopotecanDNA topoisomerase 1target
DB01030TopotecanATP-binding cassette sub-family G member 2transporter
DB01030TopotecanMultidrug resistance protein 1transporter
DB01030TopotecanCytochrome P450 3A4enzyme
DB01030TopotecanDNAtarget
DB01033MercaptopurineThiopurine S-methyltransferaseenzyme
DB01033MercaptopurineXanthine dehydrogenase/oxidaseenzyme
DB01033MercaptopurineHypoxanthine-guanine phosphoribosyltransferasetarget
DB01033MercaptopurineSolute carrier family 22 member 8transporter
DB01033MercaptopurineMultidrug resistance-associated protein 4transporter
DB01033MercaptopurineMultidrug resistance-associated protein 5transporter
DB01033MercaptopurineSodium/nucleoside cotransporter 2transporter
DB01033MercaptopurineSolute carrier family 28 member 3transporter
DB01033MercaptopurineEquilibrative nucleoside transporter 1transporter
DB01033MercaptopurineEquilibrative nucleoside transporter 2transporter
DB01033MercaptopurineAldehyde oxidaseenzyme
DB01033MercaptopurineAmidophosphoribosyltransferasetarget
DB01033MercaptopurineInosine-5'-monophosphate dehydrogenasetarget
DB01041ThalidomideTumor necrosis factortarget
DB01041ThalidomideNuclear factor NF-kappa-B p105 subunittarget
DB01041ThalidomideProstaglandin G/H synthase 2target
DB01041ThalidomideCytochrome P450 2C19enzyme
DB01041ThalidomideCytochrome P450 1A2enzyme
DB01041ThalidomideCytochrome P450 1A1enzyme
DB01041ThalidomideCytochrome P450 2E1enzyme
DB01041ThalidomideCytochrome P450 2C9enzyme
DB01041ThalidomideProstaglandin G/H synthase 1enzyme
DB01041ThalidomideProstaglandin G/H synthase 2enzyme
DB01041ThalidomideCytochrome P450 3A5enzyme
DB01041ThalidomideFibroblast growth factor receptor 2target
DB01041ThalidomideDNAtarget
DB01041ThalidomideProtein cereblontarget
DB01041ThalidomideNuclear factor kappa-light-chain-enhancer of activated B cellstarget
DB01041Thalidomidealpha1-acid glycoproteintarget
DB01042MelphalanDNAtarget
DB01042MelphalanSolute carrier family 22 member 3transporter
DB01042MelphalanLarge neutral amino acids transporter small subunit 1transporter
DB01073FludarabineDNA polymerase alpha catalytic subunittarget
DB01073FludarabineRibonucleoside-diphosphate reductase large subunittarget
DB01073FludarabineEquilibrative nucleoside transporter 1transporter
DB01073FludarabineDNAtarget
DB01073FludarabineDeoxycytidine kinasetarget
DB01073FludarabineSolute carrier family 28 member 3transporter
DB01097LeflunomideDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB01097LeflunomideCytochrome P450 1A2enzyme
DB01097LeflunomideCytochrome P450 2C9enzyme
DB01097LeflunomideAryl hydrocarbon receptortarget
DB01097LeflunomideProtein-tyrosine kinase 2-betatarget
DB01097LeflunomideATP-binding cassette sub-family G member 2transporter
DB01101CapecitabineThymidylate synthasetarget
DB01101CapecitabineThymidine phosphorylaseenzyme
DB01101CapecitabineCytidine deaminaseenzyme
DB01101CapecitabineLiver carboxylesterase 1enzyme
DB01101CapecitabineDihydropyrimidine dehydrogenase [NADP(+)]enzyme
DB01101CapecitabineCytochrome P450 2C9enzyme
DB01101CapecitabineDNAtarget
DB01101CapecitabineRNAtarget
DB01128BicalutamideAndrogen receptortarget
DB01128BicalutamideCytochrome P450 3A4enzyme
DB01128BicalutamideCytochrome P450 2C19enzyme
DB01128BicalutamideCytochrome P450 2C9enzyme
DB01128BicalutamideCytochrome P450 2D6enzyme
DB01168ProcarbazineDNAtarget
DB01168ProcarbazineXanthine dehydrogenase/oxidaseenzyme
DB01168ProcarbazineCytochrome P450 1B1enzyme
DB01168ProcarbazineMonoamine oxidasetarget
DB01169Arsenic trioxideInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB01169Arsenic trioxideTranscription factor AP-1target
DB01169Arsenic trioxideG1/S-specific cyclin-D1target
DB01169Arsenic trioxideMitogen-activated protein kinase 3target
DB01169Arsenic trioxideMitogen-activated protein kinase 1target
DB01169Arsenic trioxideRAC-alpha serine/threonine-protein kinasetarget
DB01169Arsenic trioxideCytochrome P450 1A1enzyme
DB01169Arsenic trioxideCanalicular multispecific organic anion transporter 1transporter
DB01169Arsenic trioxideThioredoxin reductase 1, cytoplasmictarget
DB01169Arsenic trioxideMultidrug resistance protein 1transporter
DB01169Arsenic trioxideCytochrome P450 1B1enzyme
DB01169Arsenic trioxideCytochrome P450 3A4enzyme
DB01169Arsenic trioxideCyclin-dependent kinase inhibitor 1target
DB01169Arsenic trioxideHistone deacetylase 1target
DB01169Arsenic trioxideProtein PMLtarget
DB01169Arsenic trioxideSerum albumincarrier
DB01177IdarubicinDNA topoisomerase 2-alphatarget
DB01177IdarubicinDNAtarget
DB01177IdarubicinMultidrug resistance-associated protein 1transporter
DB01177IdarubicinCytochrome P450 2C9enzyme
DB01177IdarubicinCytochrome P450 2D6enzyme
DB01181IfosfamideCytochrome P450 2B6enzyme
DB01181IfosfamideDNAtarget
DB01181IfosfamideCytochrome P450 3A4enzyme
DB01181IfosfamideCytochrome P450 3A5enzyme
DB01181IfosfamideCytochrome P450 2C9enzyme
DB01181IfosfamideCytochrome P450 2C8enzyme
DB01181IfosfamideCytochrome P450 2A6enzyme
DB01181IfosfamideCytochrome P450 2C19enzyme
DB01181IfosfamideCytochrome P450 2C18enzyme
DB01181IfosfamideProstaglandin G/H synthase 1enzyme
DB01181IfosfamideCytochrome P450 3A7enzyme
DB01181IfosfamideNuclear receptor subfamily 1 group I member 2target
DB01196EstramustineEstrogen receptor betatarget
DB01196EstramustineEstrogen receptor alphatarget
DB01196EstramustineMicrotubule-associated protein 2target
DB01196EstramustineMicrotubule-associated protein 1Atarget
DB01196EstramustineMultidrug resistance protein 1transporter
DB01196EstramustineCytochrome P450 3A4enzyme
DB01204MitoxantroneDNA topoisomerase 2-alphatarget
DB01204MitoxantroneCytochrome P450 2E1enzyme
DB01204MitoxantroneMultidrug resistance protein 1transporter
DB01204MitoxantroneMultidrug resistance-associated protein 1transporter
DB01204MitoxantroneATP-binding cassette sub-family G member 2transporter
DB01204MitoxantroneDNAtarget
DB01204MitoxantroneCytochrome P450 1B1enzyme
DB01204MitoxantroneCytochrome P450 3A4enzyme
DB01206LomustineDNAtarget
DB01206LomustineCytochrome P450 3A4enzyme
DB01206LomustineCytochrome P450 2D6enzyme
DB01206LomustineStathmin-4target
DB01217AnastrozoleCytochrome P450 19A1target
DB01217AnastrozoleCytochrome P450 19A1enzyme
DB01217AnastrozoleCytochrome P450 1A2enzyme
DB01217AnastrozoleCytochrome P450 2C9enzyme
DB01217AnastrozoleCytochrome P450 3A4enzyme
DB01229PaclitaxelApoptosis regulator Bcl-2target
DB01229PaclitaxelTubulin beta-1 chaintarget
DB01229PaclitaxelCytochrome P450 2C8enzyme
DB01229PaclitaxelCytochrome P450 3A4enzyme
DB01229PaclitaxelCytochrome P450 3A5enzyme
DB01229PaclitaxelCytochrome P450 3A7enzyme
DB01229PaclitaxelCytochrome P450 2C9enzyme
DB01229PaclitaxelBile salt export pumptransporter
DB01229PaclitaxelMultidrug resistance protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 7transporter
DB01229PaclitaxelCytochrome P450 19A1enzyme
DB01229PaclitaxelCytochrome P450 1B1enzyme
DB01229PaclitaxelSolute carrier organic anion transporter family member 1B3transporter
DB01229PaclitaxelNuclear receptor subfamily 1 group I member 2target
DB01229PaclitaxelMicrotubule-associated protein 4target
DB01229PaclitaxelMicrotubule-associated protein 2target
DB01229PaclitaxelMicrotubule-associated protein tautarget
DB01229PaclitaxelATP-binding cassette sub-family G member 2transporter
DB01229PaclitaxelCanalicular multispecific organic anion transporter 1transporter
DB01248DocetaxelApoptosis regulator Bcl-2target
DB01248DocetaxelTubulin beta-1 chaintarget
DB01248DocetaxelCytochrome P450 3A4enzyme
DB01248DocetaxelCytochrome P450 3A5enzyme
DB01248DocetaxelCytochrome P450 3A7enzyme
DB01248DocetaxelMultidrug resistance protein 1transporter
DB01248DocetaxelMultidrug resistance-associated protein 7transporter
DB01248DocetaxelCytochrome P450 1B1enzyme
DB01248DocetaxelMicrotubule-associated protein 2target
DB01248DocetaxelMicrotubule-associated protein 4target
DB01248DocetaxelMicrotubule-associated protein tautarget
DB01248DocetaxelSolute carrier organic anion transporter family member 1B3transporter
DB01248DocetaxelSolute carrier family 22 member 7transporter
DB01248DocetaxelATP-binding cassette sub-family G member 2transporter
DB01248DocetaxelCanalicular multispecific organic anion transporter 1transporter
DB01248DocetaxelMultidrug resistance-associated protein 1transporter
DB01248DocetaxelNuclear receptor subfamily 1 group I member 2target
DB01254DasatinibTyrosine-protein kinase ABL1target
DB01254DasatinibAbelson tyrosine-protein kinase 2target
DB01254DasatinibProto-oncogene tyrosine-protein kinase Srctarget
DB01254DasatinibTyrosine-protein kinase Fyntarget
DB01254DasatinibTyrosine-protein kinase Lcktarget
DB01254DasatinibTyrosine-protein kinase Yestarget
DB01254DasatinibMast/stem cell growth factor receptor Kittarget
DB01254DasatinibPlatelet-derived growth factor receptor betatarget
DB01254DasatinibEphrin type-A receptor 2target
DB01254DasatinibSignal transducer and activator of transcription 5Btarget
DB01254DasatinibCytochrome P450 3A4enzyme
DB01254DasatinibMultidrug resistance protein 1transporter
DB01254DasatinibATP-binding cassette sub-family G member 2transporter
DB01254DasatinibCytochrome P450 1A1enzyme
DB01254DasatinibCytochrome P450 1A2enzyme
DB01254DasatinibCytochrome P450 1B1enzyme
DB01254DasatinibCytochrome P450 3A5enzyme
DB01254DasatinibDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB01254DasatinibTyrosine-protein kinase BTKtarget
DB01254DasatinibNuclear receptor subfamily 4 group A member 3target
DB01254DasatinibBreakpoint cluster region proteintarget
DB01254DasatinibTyrosine-protein kinase CSKtarget
DB01254DasatinibEphrin type-A receptor 5target
DB01254DasatinibEphrin type-B receptor 4target
DB01254DasatinibTyrosine-protein kinase Fgrtarget
DB01254DasatinibTyrosine-protein kinase FRKtarget
DB01254DasatinibHeat shock cognate 71 kDa proteintarget
DB01254DasatinibTyrosine-protein kinase Lyntarget
DB01254DasatinibMitogen-activated protein kinase kinase kinase MLTtarget
DB01254DasatinibMitogen-activated protein kinase 14target
DB01254DasatinibAmidophosphoribosyltransferasetarget
DB01257EculizumabComplement C5target
DB01259LapatinibEpidermal growth factor receptortarget
DB01259LapatinibReceptor tyrosine-protein kinase erbB-2target
DB01259LapatinibCytochrome P450 3A4enzyme
DB01259LapatinibCytochrome P450 2C8enzyme
DB01259LapatinibMultidrug resistance protein 1transporter
DB01259LapatinibAntigen peptide transporter 1transporter
DB01259LapatinibCytochrome P450 3A5enzyme
DB01259LapatinibCytochrome P450 2C19enzyme
DB01262DecitabineDNAtarget
DB01262DecitabineDNA (cytosine-5)-methyltransferase 1target
DB01262DecitabineDeoxycytidine kinaseenzyme
DB01268SunitinibPlatelet-derived growth factor receptor betatarget
DB01268SunitinibVascular endothelial growth factor receptor 1target
DB01268SunitinibVascular endothelial growth factor receptor 2target
DB01268SunitinibVascular endothelial growth factor receptor 3target
DB01268SunitinibMast/stem cell growth factor receptor Kittarget
DB01268SunitinibReceptor-type tyrosine-protein kinase FLT3target
DB01268SunitinibMacrophage colony-stimulating factor 1 receptortarget
DB01268SunitinibPlatelet-derived growth factor receptor alphatarget
DB01268SunitinibCytochrome P450 3A4enzyme
DB01268SunitinibCytochrome P450 3A5enzyme
DB01268SunitinibCytochrome P450 3A7enzyme
DB01268SunitinibMultidrug resistance-associated protein 4transporter
DB01268SunitinibMultidrug resistance protein 1transporter
DB01268SunitinibCanalicular multispecific organic anion transporter 1transporter
DB01268SunitinibATP-binding cassette sub-family G member 2transporter
DB01269PanitumumabEpidermal growth factor receptortarget
DB01280NelarabineDNAtarget
DB01280NelarabineAdenosine deaminaseenzyme
DB01280NelarabineDeoxycytidine kinaseenzyme
DB01280NelarabineDeoxyguanosine kinase, mitochondrialenzyme
DB01280NelarabineDNA polymerase alpha catalytic subunittarget
DB01281AbataceptT-lymphocyte activation antigen CD80target
DB01281AbataceptT-lymphocyte activation antigen CD86target
DB01590EverolimusSerine/threonine-protein kinase mTORtarget
DB01590EverolimusCytochrome P450 3A4enzyme
DB02546VorinostatHistone deacetylase 1target
DB02546VorinostatHistone deacetylase 2target
DB02546VorinostatHistone deacetylase 3target
DB02546VorinostatHistone deacetylase 6target
DB02546VorinostatHistone deacetylase 8target
DB02546VorinostatAcetoin utilization proteintarget
DB04106FotemustineThioredoxin reductase 1, cytoplasmictarget
DB04572ThiotepaCytochrome P450 2B6enzyme
DB04572ThiotepaCytochrome P450 3A4enzyme
DB04572ThiotepaDNAtarget
DB04845IxabepiloneTubulin beta-3 chaintarget
DB04845IxabepiloneCytochrome P450 3A4enzyme
DB04849CediranibVascular endothelial growth factor receptor 2target
DB04865Omacetaxine mepesuccinate50S ribosomal protein L2target
DB04865Omacetaxine mepesuccinate60S ribosomal protein L3target
DB04868NilotinibTyrosine-protein kinase ABL1target
DB04868NilotinibMast/stem cell growth factor receptor Kittarget
DB04868NilotinibCytochrome P450 2D6enzyme
DB04868NilotinibCytochrome P450 2C8enzyme
DB04868NilotinibCytochrome P450 2C9enzyme
DB04868NilotinibCytochrome P450 3A4enzyme
DB04868NilotinibMultidrug resistance protein 1transporter
DB04868NilotinibATP-binding cassette sub-family G member 2transporter
DB04868NilotinibUDP-glucuronosyltransferase 1-1transporter
DB04868NilotinibCytochrome P450 2B6enzyme
DB04951PirfenidoneFurintarget
DB04956AfelimomabTumor necrosis factortarget
DB04996SatraplatinDNAtarget
DB05015BelinostatHistone deacetylasetarget
DB05015BelinostatCytochrome P450 1A2enzyme
DB05015BelinostatUDP-glucuronosyltransferase 1A1enzyme
DB05015BelinostatCytochrome P450 2C8enzyme
DB05015BelinostatCytochrome P450 2C9enzyme
DB05015BelinostatMultidrug resistance protein 1transporter
DB05109TrabectedinCytochrome P450 3A4enzyme
DB05109TrabectedinCytochrome P450 2C9enzyme
DB05109TrabectedinCytochrome P450 2D6enzyme
DB05109TrabectedinCytochrome P450 2E1enzyme
DB05109TrabectedinCytochrome P450 2C19enzyme
DB05109TrabectedinDNAtarget
DB05109TrabectedinProstaglandin G/H synthase 1enzyme
DB05168VintafolideFolate receptor betatarget
DB05168VintafolideFolate receptor gammatarget
DB05168VintafolideFolate receptor alphatarget
DB05259Glatiramer AcetateHLA class II histocompatibility antigen, DRB1-1 beta chaintarget
DB05294VandetanibVascular endothelial growth factor Atarget
DB05294VandetanibEpidermal growth factor receptortarget
DB05294VandetanibMultidrug resistance-associated protein 1transporter
DB05294VandetanibATP-binding cassette sub-family G member 2transporter
DB05294VandetanibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB05294VandetanibDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB05294VandetanibDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB05294VandetanibProtein-tyrosine kinase 6target
DB05294VandetanibAngiopoietin-1 receptortarget
DB05294VandetanibAlpha-1-acid glycoprotein 1carrier
DB05294VandetanibSerum albumincarrier
DB05294VandetanibCytochrome P450 3A4enzyme
DB05459BriakinumabInterleukin-12 subunit betatarget
DB05459BriakinumabInterleukin-23 subunit alphatarget
DB05578RamucirumabVascular endothelial growth factor receptor 2target
DB05676ApremilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB05676ApremilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB05676ApremilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB05676ApremilastTumor necrosis factortarget
DB05676ApremilastInterleukin-2target
DB05676ApremilastInterferon gammatarget
DB05676ApremilastNitric oxide synthase, endothelialtarget
DB05676ApremilastCytochrome P450 3A4enzyme
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineMultidrug resistance protein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB05812AbirateroneSteroid 17-alpha-hydroxylase/17,20 lyasetarget
DB05812AbirateroneSerum albumincarrier
DB05812AbirateroneAlpha-1-acid glycoprotein 1carrier
DB05812AbirateroneCytochrome P450 3A4enzyme
DB05812AbirateroneBile salt sulfotransferaseenzyme
DB05812AbirateroneMultidrug resistance-associated protein 1transporter
DB05812AbirateroneCytochrome P450 2D6enzyme
DB05812AbirateroneCytochrome P450 2C8enzyme
DB05812AbirateroneCytochrome P450 1A2enzyme
DB05812AbirateroneCytochrome P450 2C19enzyme
DB05812AbirateroneCytochrome P450 2C9enzyme
DB06168CanakinumabInterleukin-1 betatarget
DB06176RomidepsinCytochrome P450 3A4enzyme
DB06176RomidepsinCytochrome P450 3A5enzyme
DB06176RomidepsinMultidrug resistance protein 1transporter
DB06176RomidepsinSolute carrier organic anion transporter family member 1B3transporter
DB06176RomidepsinCytochrome P450 1A1enzyme
DB06176RomidepsinCytochrome P450 2B6enzyme
DB06176RomidepsinCytochrome P450 2C19enzyme
DB06176RomidepsinHistone deacetylase 1target
DB06176RomidepsinHistone deacetylase 2target
DB06176RomidepsinHistone deacetylase 4target
DB06176RomidepsinHistone deacetylase 6target
DB06176RomidepsinMultidrug resistance-associated protein 1target
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB06263AmrubicinDNA topoisomerase 2-alphatarget
DB06263AmrubicinDNAtarget
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06287TemsirolimusSerine/threonine-protein kinase mTORtarget
DB06287TemsirolimusCytochrome P450 3A4enzyme
DB06287TemsirolimusCytochrome P450 3A5enzyme
DB06287TemsirolimusCytochrome P450 3A7enzyme
DB06287TemsirolimusCytochrome P450 2D6enzyme
DB06287TemsirolimusMultidrug resistance protein 1transporter
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB06372RilonaceptInterleukin-1 betatarget
DB06372RilonaceptInterleukin-1 alphatarget
DB06372RilonaceptInterleukin-1 receptor antagonist proteintarget
DB06589PazopanibVascular endothelial growth factor receptor 1target
DB06589PazopanibVascular endothelial growth factor receptor 2target
DB06589PazopanibVascular endothelial growth factor receptor 3target
DB06589PazopanibPlatelet-derived growth factor receptor alphatarget
DB06589PazopanibPlatelet-derived growth factor receptor betatarget
DB06589PazopanibMast/stem cell growth factor receptor Kittarget
DB06589PazopanibCytochrome P450 3A4enzyme
DB06589PazopanibCytochrome P450 2D6enzyme
DB06589PazopanibCytochrome P450 2C8enzyme
DB06589PazopanibCytochrome P450 1A2enzyme
DB06589PazopanibMultidrug resistance protein 1transporter
DB06589PazopanibATP-binding cassette sub-family G member 2transporter
DB06589PazopanibSolute carrier organic anion transporter family member 1B1transporter
DB06589PazopanibUDP-glucuronosyltransferase 1-1transporter
DB06589PazopanibFibroblast growth factor receptor 3target
DB06589PazopanibTyrosine-protein kinase ITK/TSKtarget
DB06589PazopanibFibroblast growth factor 1target
DB06589PazopanibSH2B adapter protein 3target
DB06603PanobinostatCytochrome P450 2D6enzyme
DB06603PanobinostatCytochrome P450 3A4enzyme
DB06603PanobinostatMultidrug resistance protein 1transporter
DB06603PanobinostatHistone deacetylasetarget
DB06612MepolizumabInterleukin-5target
DB06616BosutinibBreakpoint cluster region proteintarget
DB06616BosutinibTyrosine-protein kinase ABL1target
DB06616BosutinibTyrosine-protein kinase Lyntarget
DB06616BosutinibTyrosine-protein kinase HCKtarget
DB06616BosutinibProto-oncogene tyrosine-protein kinase Srctarget
DB06616BosutinibMultidrug resistance protein 1transporter
DB06616BosutinibCytochrome P450 3A4enzyme
DB06616BosutinibCyclin-dependent kinase 2target
DB06616BosutinibDual specificity mitogen-activated protein kinase kinase 1target
DB06616BosutinibDual specificity mitogen-activated protein kinase kinase 2target
DB06616BosutinibMitogen-activated protein kinase kinase kinase 2target
DB06616BosutinibCalcium/calmodulin-dependent protein kinase type II subunit gammatarget
DB06626AxitinibVascular endothelial growth factor receptor 1target
DB06626AxitinibVascular endothelial growth factor receptor 2target
DB06626AxitinibVascular endothelial growth factor receptor 3target
DB06626AxitinibCytochrome P450 3A4enzyme
DB06626AxitinibCytochrome P450 3A5enzyme
DB06626AxitinibCytochrome P450 1A2enzyme
DB06626AxitinibCytochrome P450 2C19enzyme
DB06626AxitinibUDP-glucuronosyltransferase 1-1enzyme
DB06626AxitinibMultidrug resistance protein 1transporter
DB06626AxitinibSolute carrier organic anion transporter family member 1B1transporter
DB06650OfatumumabB-lymphocyte antigen CD20target
DB06674GolimumabTumor necrosis factortarget
DB06681BelataceptT-lymphocyte activation antigen CD86target
DB06681BelataceptT-lymphocyte activation antigen CD80target
DB06688Sipuleucel-TProstatic acid phosphatasetarget
DB06699DegarelixGonadotropin-releasing hormone receptortarget
DB06719BuserelinLutropin-choriogonadotropic hormone receptortarget
DB06719BuserelinGonadotropin-releasing hormone receptortarget
DB06719BuserelinCytochrome P450 19A1enzyme
DB06769BendamustineCytochrome P450 1A2enzyme
DB06772CabazitaxelCytochrome P450 3A4enzyme
DB06772CabazitaxelCytochrome P450 3A5enzyme
DB06772CabazitaxelCytochrome P450 2C8enzyme
DB06772CabazitaxelMultidrug resistance protein 1transporter
DB06772CabazitaxelATP-binding cassette sub-family G member 2transporter
DB06772CabazitaxelTubulin alpha-4A chaintarget
DB06772CabazitaxelTubulin beta-1 chaintarget
DB06772CabazitaxelSolute carrier organic anion transporter family member 1B1transporter
DB06772CabazitaxelSolute carrier organic anion transporter family member 1B3transporter
DB06788HistrelinGonadotropin-releasing hormone receptortarget
DB06809PlerixaforC-X-C chemokine receptor type 4target
DB06810PlicamycinDNAtarget
DB06813PralatrexateFolylpolyglutamate synthase, mitochondrialenzyme
DB06813PralatrexateDihydrofolate reductasetarget
DB06813PralatrexateThymidylate synthasetarget
DB06813PralatrexateFolate transporter 1transporter
DB06825TriptorelinGonadotropin-releasing hormone receptortarget
DB08486EfaproxiralHemoglobin subunit alphatarget
DB08486EfaproxiralHemoglobin subunit betatarget
DB08828VismodegibSmoothened homologtarget
DB08828VismodegibCytochrome P450 2C9enzyme
DB08828VismodegibCytochrome P450 3A4enzyme
DB08828VismodegibMultidrug resistance protein 1transporter
DB08828VismodegibCytochrome P450 2C8enzyme
DB08828VismodegibCytochrome P450 2C19enzyme
DB08828VismodegibATP-binding cassette sub-family G member 2transporter
DB08828VismodegibSerum albumincarrier
DB08828VismodegibAlpha-1-acid glycoprotein 1carrier
DB08865CrizotinibCytochrome P450 3A4enzyme
DB08865CrizotinibCytochrome P450 3A5enzyme
DB08865CrizotinibMultidrug resistance protein 1transporter
DB08865CrizotinibALK tyrosine kinase receptortarget
DB08865CrizotinibHepatocyte growth factor receptortarget
DB08865CrizotinibCytochrome P450 2B6enzyme
DB08868FingolimodLeukotriene-B(4) omega-hydroxylase 1enzyme
DB08868FingolimodSphingosine 1-phosphate receptor 5target
DB08868FingolimodSphingosine kinase 1enzyme
DB08868FingolimodCytochrome P450 2D6enzyme
DB08868FingolimodCytochrome P450 2E1enzyme
DB08868FingolimodCytochrome P450 3A4enzyme
DB08868FingolimodCytochrome P450 4F12enzyme
DB08868FingolimodHistone deacetylase 1target
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinCytochrome P450 3A5enzyme
DB08870Brentuximab vedotinMultidrug resistance protein 1transporter
DB08871EribulinApoptosis regulator Bcl-2target
DB08871EribulinTubulin beta-1 chaintarget
DB08875CabozantinibCytochrome P450 3A4enzyme
DB08875CabozantinibCytochrome P450 2C9enzyme
DB08875CabozantinibHepatocyte growth factor receptortarget
DB08875CabozantinibVascular endothelial growth factor receptor 2target
DB08875CabozantinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08877RuxolitinibTyrosine-protein kinase JAK1target
DB08877RuxolitinibTyrosine-protein kinase JAK2target
DB08877RuxolitinibCytochrome P450 3A4enzyme
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08880TeriflunomideATP-binding cassette sub-family G member 2transporter
DB08880TeriflunomideDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB08880TeriflunomideCytochrome P450 2C8enzyme
DB08881VemurafenibSerum albumincarrier
DB08881VemurafenibAlpha-1-acid glycoprotein 1carrier
DB08881VemurafenibCytochrome P450 1A2enzyme
DB08881VemurafenibCytochrome P450 2D6enzyme
DB08881VemurafenibCytochrome P450 3A4enzyme
DB08881VemurafenibSerine/threonine-protein kinase B-raftarget
DB08881VemurafenibMultidrug resistance-associated protein 1transporter
DB08881VemurafenibATP-binding cassette sub-family G member 2transporter
DB08889CarfilzomibMultidrug resistance protein 1transporter
DB08889CarfilzomibProteasome subunit beta type-5target
DB08889CarfilzomibProteasome subunit beta type-9target
DB08889CarfilzomibProteasome subunit beta type-10target
DB08889CarfilzomibProteasome subunit beta type-8target
DB08889CarfilzomibProteasome subunit beta type-1target
DB08889CarfilzomibProteasome subunit beta type-2target
DB08895TofacitinibNon-receptor tyrosine-protein kinase TYK2target
DB08895TofacitinibCytochrome P450 3A4enzyme
DB08895TofacitinibCytochrome P450 2C19enzyme
DB08895TofacitinibTyrosine-protein kinase JAK2target
DB08895TofacitinibTyrosine-protein kinase JAK1target
DB08895TofacitinibTyrosine-protein kinase JAK3target
DB08895TofacitinibSerum albumincarrier
DB08896RegorafenibCytochrome P450 3A4enzyme
DB08896RegorafenibUDP-glucuronosyltransferase 1-9enzyme
DB08896RegorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08896RegorafenibVascular endothelial growth factor receptor 1target
DB08896RegorafenibVascular endothelial growth factor receptor 2target
DB08896RegorafenibVascular endothelial growth factor receptor 3target
DB08896RegorafenibMast/stem cell growth factor receptor Kittarget
DB08896RegorafenibPlatelet-derived growth factor receptor alphatarget
DB08896RegorafenibPlatelet-derived growth factor receptor betatarget
DB08896RegorafenibFibroblast growth factor receptor 1target
DB08896RegorafenibFibroblast growth factor receptor 2target
DB08896RegorafenibAngiopoietin-1 receptortarget
DB08896RegorafenibDiscoidin domain-containing receptor 2target
DB08896RegorafenibHigh affinity nerve growth factor receptortarget
DB08896RegorafenibEphrin type-A receptor 2target
DB08896RegorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08896RegorafenibSerine/threonine-protein kinase B-raftarget
DB08896RegorafenibCytochrome P450 2C8enzyme
DB08896RegorafenibCytochrome P450 2C9enzyme
DB08896RegorafenibCytochrome P450 2B6enzyme
DB08896RegorafenibCytochrome P450 2C19enzyme
DB08896RegorafenibMitogen-activated protein kinase 11target
DB08896RegorafenibTyrosine-protein kinase FRKtarget
DB08896RegorafenibTyrosine-protein kinase ABL1target
DB08896RegorafenibMultidrug resistance protein 1transporter
DB08896RegorafenibATP-binding cassette sub-family G member 2transporter
DB08896RegorafenibUDP-glucuronosyltransferase 1-1enzyme
DB08899EnzalutamideSerum albumincarrier
DB08899EnzalutamideCytochrome P450 2C8enzyme
DB08899EnzalutamideCytochrome P450 3A4enzyme
DB08899EnzalutamideAndrogen receptortarget
DB08899EnzalutamideCytochrome P450 2C9enzyme
DB08899EnzalutamideCytochrome P450 2C19enzyme
DB08899EnzalutamideCytochrome P450 2B6enzyme
DB08899EnzalutamideCytochrome P450 2D6enzyme
DB08899EnzalutamideCytochrome P450 3A5enzyme
DB08899EnzalutamideMultidrug resistance protein 1transporter
DB08901PonatinibTyrosine-protein kinase ABL1target
DB08901PonatinibBreakpoint cluster region proteintarget
DB08901PonatinibMast/stem cell growth factor receptor Kittarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08901PonatinibAngiopoietin-1 receptortarget
DB08901PonatinibReceptor-type tyrosine-protein kinase FLT3target
DB08901PonatinibCytochrome P450 3A4enzyme
DB08901PonatinibCytochrome P450 2C8enzyme
DB08901PonatinibCytochrome P450 2D6enzyme
DB08901PonatinibCytochrome P450 3A5enzyme
DB08901PonatinibMultidrug resistance protein 1transporter
DB08901PonatinibATP-binding cassette sub-family G member 2transporter
DB08901PonatinibFibroblast growth factor receptor 1target
DB08901PonatinibFibroblast growth factor receptor 2target
DB08901PonatinibFibroblast growth factor receptor 3target
DB08901PonatinibFibroblast growth factor receptor 4target
DB08901PonatinibTyrosine-protein kinase Lcktarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase Srctarget
DB08901PonatinibTyrosine-protein kinase Lyntarget
DB08901PonatinibVascular endothelial growth factor receptor 2target
DB08901PonatinibPlatelet-derived growth factor receptor alphatarget
DB08901PonatinibBile salt export pumptransporter
DB08904Certolizumab pegolTumor necrosis factortarget
DB08910PomalidomideCytochrome P450 1A2enzyme
DB08910PomalidomideCytochrome P450 3A4enzyme
DB08910PomalidomideMultidrug resistance protein 1transporter
DB08910PomalidomideProtein cereblontarget
DB08910PomalidomideTumor necrosis factortarget
DB08910PomalidomideProstaglandin G/H synthase 2target
DB08911TrametinibCytochrome P450 2C8enzyme
DB08911TrametinibCytochrome P450 3A4enzyme
DB08911TrametinibDual specificity mitogen-activated protein kinase kinase 1target
DB08911TrametinibDual specificity mitogen-activated protein kinase kinase 2target
DB08912DabrafenibCytochrome P450 3A4enzyme
DB08912DabrafenibCytochrome P450 2C8enzyme
DB08912DabrafenibMultidrug resistance protein 1transporter
DB08912DabrafenibATP-binding cassette sub-family G member 2transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B1transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B3transporter
DB08912DabrafenibSolute carrier family 22 member 6transporter
DB08912DabrafenibSolute carrier family 22 member 8transporter
DB08912DabrafenibSerine/threonine-protein kinase B-raftarget
DB08912DabrafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08912DabrafenibSerine/threonine-protein kinase SIK1target
DB08912DabrafenibSerine/threonine-protein kinase Nek11target
DB08912DabrafenibLIM domain kinase 1target
DB08916AfatinibEpidermal growth factor receptortarget
DB08916AfatinibReceptor tyrosine-protein kinase erbB-2target
DB08916AfatinibReceptor tyrosine-protein kinase erbB-4target
DB08916AfatinibMultidrug resistance protein 1transporter
DB08916AfatinibATP-binding cassette sub-family G member 2transporter
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09029SecukinumabInterleukin-17Atarget
DB09031MiltefosinePhospholipase D1enzyme
DB09031MiltefosineMultidrug resistance protein 1target
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB09035NivolumabProgrammed cell death protein 1target
DB09036SiltuximabInterleukin-6target
DB09037PembrolizumabProgrammed cell death protein 1target
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09053IbrutinibTyrosine-protein kinase BTKtarget
DB09053IbrutinibCytochrome P450 3A4enzyme
DB09053IbrutinibCytochrome P450 3A5enzyme
DB09053IbrutinibCytochrome P450 2D6enzyme
DB09054IdelalisibPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)target
DB09054IdelalisibATP-binding cassette sub-family G member 2transporter
DB09054IdelalisibMultidrug resistance protein 1transporter
DB09054IdelalisibAldehyde oxidaseenzyme
DB09054IdelalisibCytochrome p450 3A subfamilyenzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A4enzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A1enzyme
DB09054IdelalisibCytochrome P450 2C8enzyme
DB09054IdelalisibCytochrome P450 2C19enzyme
DB09054IdelalisibCytochrome P450 2B6enzyme
DB09054IdelalisibCytochrome P450 3A4enzyme
DB09054IdelalisibSolute carrier organic anion transporter family member 1B1transporter
DB09054IdelalisibSolute carrier organic anion transporter family member 1B3transporter
DB09063CeritinibALK tyrosine kinase receptortarget
DB09063CeritinibMultidrug resistance protein 1transporter
DB09063CeritinibCytochrome P450 3A4enzyme
DB09063CeritinibCytochrome P450 2C9enzyme
DB09073PalbociclibCyclin-dependent kinase 4target
DB09073PalbociclibCyclin-dependent kinase 6target
DB09073PalbociclibCytochrome P450 3A4enzyme
DB09073PalbociclibSulfotransferase 2A1enzyme
DB09074OlaparibPoly [ADP-ribose] polymerase 1target
DB09074OlaparibCytochrome P450 3A4enzyme
DB09074OlaparibCytochrome P450 2B6enzyme
DB09074OlaparibPoly [ADP-ribose] polymerase 2target
DB09074OlaparibPoly [ADP-ribose] polymerase 3target
DB09077DinutuximabGanglioside GD2target
DB09078LenvatinibVascular endothelial growth factor receptor 1target
DB09078LenvatinibVascular endothelial growth factor receptor 2target
DB09078LenvatinibVascular endothelial growth factor receptor 3target
DB09078LenvatinibFibroblast growth factor receptor 1target
DB09078LenvatinibFibroblast growth factor receptor 2target
DB09078LenvatinibFibroblast growth factor receptor 3target
DB09078LenvatinibFibroblast growth factor receptor 4target
DB09078LenvatinibPlatelet derived growth factor receptor alphatarget
DB09078LenvatinibRET target
DB09078LenvatinibMast/stem cell growth factor receptor Kittarget
DB09078LenvatinibMultidrug resistance protein 1transporter
DB09078LenvatinibATP-binding cassette sub-family G member 2transporter
DB09078LenvatinibCytochrome P450 3A4enzyme
DB09078LenvatinibAldehyde oxidaseenzyme
DB09079NintedanibVascular endothelial growth factor receptor 1target
DB09079NintedanibVascular endothelial growth factor receptor 2target
DB09079NintedanibVascular endothelial growth factor receptor 3target
DB09079NintedanibPlatelet derived growth factor receptor alphatarget
DB09079NintedanibPlatelet derived growth factor receptor betatarget
DB09079NintedanibFibroblast growth factor receptor 1target
DB09079NintedanibFibroblast growth factor receptor 2target
DB09079NintedanibFibroblast growth factor receptor 3target
DB09079NintedanibReceptor-type tyrosine-protein kinase FLT3target
DB09079NintedanibTyrosine-protein kinase Lcktarget
DB09079NintedanibTyrosine-protein kinase Lyntarget
DB09079NintedanibProto-oncogene tyrosine-protein kinase Srctarget
DB09079NintedanibMultidrug resistance protein 1transporter
DB09143SonidegibSmoothened homologtarget
DB09143SonidegibCytochrome P450 3A4enzyme
DB09256TegafurCytochrome P450 2A6enzyme
DB09559NecitumumabEpidermal growth factor receptortarget
DB09570IxazomibCytochrome P450 3A4enzyme
DB09570IxazomibCytochrome P450 1A2enzyme
DB09570IxazomibCytochrome P450 2B6enzyme
DB09570IxazomibCytochrome P450 2C8enzyme
DB09570IxazomibCytochrome P450 2D6enzyme
DB09570IxazomibCytochrome P450 2C19enzyme
DB09570IxazomibCytochrome P450 2C9enzyme
DB11693VoclosporinCalcineurin subunit B type 1target
DB11693VoclosporinCalcineurin subunit B type 2target
DB13144LenograstimGranulocyte colony-stimulating factor receptortarget